FAT1 and hepatocellular carcinoma: Promotor hypomethylation was hypothesized as an explanation for aberrant FAT1 expression in HCC as treatment with hypomethylating agents 5-Aza-2′deoxacytidine, adenosine-2′,3′-dialdehyde or S-adenosyl-L-methionine augmented FAT1 expression in HCC cell lines25.